Posted by MD Biosciences on Tue, Oct 06, 2009 @ 10:45 AM
MD Biosciences (MDB) launches MD Bioproducts, a division of MD Biosciences, in a continued effort to meet client needs for high quality research products. The new division allows MD Biosciences to strengthen and expand it's product offering for immunology and cell biology research while maintaining its contract research focus within inflammation and neurology disease research.
While MD Biosciences has offered its products for purchase since 1991, the new division permits for increased product distribution by 140 percent. Cell Culture Related Reagents, Assays, Antibodies, Proteins, and Western Blot kits are some of the products MD Bioproducts currently provides. Currently, new products and product technologies are being explored and will be added to the development and manufacturing for the coming year.
"At MD Biosciences, our top priority has always been meeting the needs of our clients through the products we offer and customer experience we deliver. The launch of MD Bioproducts is a great step of convenience for our clients-accommodating them to optimize their research process. We know that our products offer accuracy and reproducibility so our clients can be confident in their results. Our quality reagents contribute to the success of our clients' research," stated MD Biosciences President, Eddie Moradian.
Apart from the key benefit of increased manufacturing opportunities, the new division provides a better resource for product purchasers. VP of Marketing & Sales, Amy Clausen said, "MD Bioproducts showcases a new, clean look--including packaging, logo and its own website, which allows for easy navigation and viewing of product features. We are thrilled to be taking this direction at MDB as it will simplify and improve the customer experience for the client." MD Bioproducts website may be visited at
www.mdbioproducts.com.
About MD BiosciencesMD Biosciences provides contract research services including efficacy testing, mode of action platforms, in vitro analysis, and histology for the Pharmaceutical, Medical Device and Animal Health & Nutrition Industries. We offer several novel models in the area of rheumatoid arthritis (RA), Multiple sclerosis, asthma, IBD, pain, and Parkinson's disease. The in-depth expertise in these disease models has been applied to designing protocols to assess the efficacy and required dosage of novel compounds. Contracted studies are designed and reviewed by MDB’s panel of internationally recognized experts and performed at one of MDB’s specialized laboratories located in St. Paul, MN (USA), Glasgow (Scotland) or in Israel. We provide a ready team of experts to tackle problems and provide solutions.
About MD BioproductsMD Bioproducts is a division of MD Biosciences offering high-quality reagents for immunology and cell biology research. Our goal is to provide products that are easy-to-use, accurate and reproducible – ultimately contributing to our client's research success.
###
The information in this press release should be considered accurate only as of the date of the release. MDB has no intention of updating and specifically disclaims any duty to update the information in these press releases.
Posted by Amy Clausen on Mon, Oct 05, 2009 @ 10:51 AM
MD Biosciences (MDB), a contract research organization offering
pre-clinical services and products in support of drug discovery for
inflammatory and neurological diseases, relocated its U.S. office from
1000 Westgate Dr, St Paul, MN to 2575 University Ave W, St Paul, MN on
October 3, 2009. The new location equips MD Biosciences with more lab
space, allowing for increased capacity for in vitro services and
product development and manufacturing to increase product offering.
Eddie
Moradian, President of MD Biosciences states, "At MD Biosciences, we
have always promised our clients that we will meet their needs now and
in the future; our expansion ensures that commitment. We doubled our
lab space so that we are able to provide 150 percent more services and
increase product development by 130 percent in the coming year in
comparison with the last.
Our relocation is just one step of
many in the endeavor to continue to offer the highest quality services
and products in assisting our customers in meeting their objectives.
Future projections include adding more highly specialized scientists to
our team and increasing our focus on our available products and
proprietary reagents."
About MD BiosciencesMD
Biosciences provides products and pre-clinical services, which include
efficacy testing, mode of action platforms, in vitro analysis,
histology and imaging for the Pharmaceutical, Medical Device and Animal
Health & Nutrition Industries. We offer several novel models in the
area of rheumatoid arthritis (RA), Multiple sclerosis, asthma, IBD,
pain, and Parkinson's disease. The in-depth expertise in these disease
models has been applied to designing protocols to assess the efficacy
and required dosage of novel compounds. Contracted studies are designed
and reviewed by MDB’s panel of internationally recognized experts and
performed at one of MDB’s specialized laboratories located in St. Paul,
MN (USA), Glasgow (Scotland) or in Israel . We provide a ready team of
experts to tackle problems and provide solutions. MDB also supplies for
purchase by all laboratories many of the products and proprietary
reagents used in our research, regardless of whether MDB is contracted
as a research organization. This allows our clients to optimize their
own research process by selecting steps to be performed by MDB and
research to be performed in-house.
###
The
information in this press release should be considered accurate only as
of the date of the release. MD Biosciences has no intention of updating
and specifically disclaims any duty to update the information in these
press releases.